Author

Remo Panaccione 1

1 University of Calgary, Calgary, Canada

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, Rachel Duan, Kristina Kligys, Marla C. Dubinsky

A RANDOMIZED THREE ARM COMPARISON OF HIGH DEFINITION ALONE WITH HIGH DEFINITION DYE SPRAYING AND ELECTRONIC VIRTUAL CHROMOENDOSCOPY USING ISCAN FOR DETECTION OF COLONIC DYSPLASTIC LESIONS DURING IBD SURVEILLANCE COLONOSCOPY

Marietta Iacucci, Miriam Fort Gasia, Stefan Urbanski, Parham Minoo, Gilaad G. Kaplan, Remo Panaccione, Subrata Ghosh

A SIMPLE ULTRASONOGRAPIC SCORE FOR THE ACCURATE DETECTION OF INFLAMMATORY ACTIVITY IN CROHN’S DISEASE

Kerri L. Novak, Gilaad G. Kaplan, Remo Panaccione, Subrata Ghosh, Elnaz Ehtshami Afshar, Emma Boyce, Stephanie R. Wilson

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

AbbVie - Are we ready to change the course of IBD?

Edouard Louis, Remo Panaccione, Laurent Peyrin-Biroulet, Jean-Frederic Colombel

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky, Scott D. Lee, Remo Panaccione, Maria T. Abreu, Severine Vermeire, Trevor Lissoos, Nathan Morris, Vipin Arora, Mingyang Shan, April Naegeli, Bruce E. Sands

ADALIMUMAB LONG-TERM EFFECTIVENESS IN ADALIMUMAB-NAIVE PATIENTS WITH CROHN'S DISEASE: FINAL DATA FROM PYRAMID REGISTRY

Edward V Loftus Jr, Geert R. D'Haens, Walter Reinisch, Jack Satsangi, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Martha Skup, Joel Petersson, Anne M. Robinson

AI AUTOMATED WORKFLOW FOR IMPROVING DETECTION AND SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY UNDER MULTIPLE SCORING SYSTEMS

Greta Laage, Michael Byrne, James East, Marietta Iacucci, Remo Panaccione, Rakesh Kalapala, Nageshwar Duvvur, Hardik Rughwani, ANIRUDDHA SINGH, Milagros Henkel, Sameer Berry, Lalit Canaran, Ludovic St-Denis, Shima Nikfal, Jerome Asselin, Ryan Monsurate, Enrico Cremonese, Florian Soudan, Simon Travis

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

Item 1 - 10 / 105
1
2 3 4 5 6 7
...
10 11